Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses.
Highly pathogenic H5N1 virus infection causes severe disease and a high rate of fatality in humans. Development of humanized monoclonal antibodies may provide an efficient therapeutic regime for H5N1 virus infection. In the present study, broadly cross-reactive monoclonal antibodies (MAbs) derived from mice were humanized to minimize immunogenicity. One chimeric antibody (cAb) and seven humanized antibodies (hAbs) were constructed. These antibodies retained broad-spectrum reactivity to H5N1 viruses, binding to recombinant H5-subtype HA1 molecules expressed in CHO cells in a dose-dependent manner and exhibiting similar reactivities against antigenically distinct H5N1 viruses in hemagglutination inhibition (HI) assays. One humanized antibody, 37 hAb, showed HI and neutralization activities comparable to that of the parental murine antibody, 13D4 MAb, while the other six antibodies were less reactive to H5N1 viruses. Analysis of amino acid sequences in the variable region frameworks of the seven humanized antibodies found that Q5 and Y27 in the VH region are highly conserved murine residues. Comparison of the three-dimensional structures derived from the variable regions of MAbs 37 hAb, H1202-34, and 13D4 revealed that residue substitutions at sites 70 and 46 may be the major cause for the observed differences in binding affinity. Examination of the chimeric antibody and one of the humanized antibodies, 37 hAb, showed that both antibodies offered postinfection protection against lethal challenge with antigenically diverse H5N1 viruses in the mouse model. Chimeric and humanized antibodies which retain the broadly reactive and protective properties of murine H5-specific monoclonal antibodies have great potential for use in the treatment of human H5N1 infection.
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, China.
Qingbing
Q
Zheng
Lin
L
Xia
Wai Lan
WL
Wu
Zhenhua
Z
Zheng
Yongting
Y
Huo
Jun
J
Wu
Yanning
Y
Liu
Hai
H
Yu
Yixin
Y
Chen
Siu-Ying
SY
Lau
Honglin
H
Chen
Wenxin
W
Luo
Ningshao
N
Xia
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D051379:Mice; D008958:Models, Molecular; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D019151:Peptide Library; D017433:Protein Structure, Secondary
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D019151:Peptide Library
Science. 2009 Apr 10;324(5924):246-51
19251591
Expert Opin Pharmacother. 2001 Oct;2(10):1671-83
11825310
Nat Struct Mol Biol. 2009 Mar;16(3):265-73
19234466
Clin Infect Dis. 2010 May 1;50(9):1258-67
20235830
J Clin Microbiol. 2005 Nov;43(11):5760-7
16272514
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2845-50
16473931
N Engl J Med. 2007 Oct 4;357(14):1450-1
17914053
Exp Clin Immunogenet. 1998;15(3):171-83
9813414
PLoS Med. 2007 May;4(5):e178
17535101
J Virol. 2008 Feb;82(4):1798-807
18077726
PLoS One. 2010 Feb 08;5(2):e9106
20161706
Euro Surveill. 2005 Dec;10(12):264-8
16371696
Lancet. 2008 Apr 26;371(9622):1427-34
18400288
Nat Biotechnol. 2007 Dec;25(12):1421-34
18066039
Arch Virol. 1991;119(1-2):37-42
1863223
PLoS One. 2008;3(12):e3942
19079604
Comp Immunol Microbiol Infect Dis. 2009 Jul;32(4):287-300
19318178
PLoS One. 2009 May 22;4(5):e5672
19478856
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7379-84
19383794
Respir Res. 2006 Oct 14;7:126
17040574
PLoS One. 2008;3(10):e3410
18923671
Front Biosci. 2008 Jan 01;13:1619-33
17981654
Science. 2009 Feb 27;323(5918):1160
19251602
Respirology. 2008 Mar;13 Suppl 1:S2-9
18366524
J Infect Dis. 2009 Dec 15;200(12):1870-3
19911992
Ann Intern Med. 2006 Oct 17;145(8):599-609
16940336
J Virol. 2009 Mar;83(6):2553-62
19109379
J Virol. 2010 Aug;84(16):8275-86
20519402
Emerg Infect Dis. 2009 Apr;15(4):552-60
19331731
J Infect Dis. 2009 Jan 1;199(1):49-58
19032063
N Engl J Med. 2008 Jan 17;358(3):261-73
18199865
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16936-41
17075062
PLoS One. 2009;4(5):e5476
19421326
N Engl J Med. 2009 Mar 5;360(10):953-6
19258250